New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
New data suggest that measuring AR-V7 expression only in the nuclei of circulating tumor cells might better predict therapeutic benefit in prostate cancer patients.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
C4BPA could prove useful as a diagnostic biomarker for early stage pancreatic cancer and to help differentiate the disease from other cancers.
The test could provide an early diagnosis of breast cancer by examining a handful of miRNA, microRNA, and proteomic biomarkers from urine samples.
ViveBio plans to develop an assay based on inflammatory protein and mRNA biomarkers for laboratory-developed and companion diagnostic testing.
NEW YORK (GenomeWeb) – BHC Center of Financial and Investment Business today announced it has invested in 20/20 GeneSystems to help bring the company's diagnostic test for lung cancer to China.
NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.
NEW YORK (GenomeWeb News) – Provista Diagnostics said today that it has licensed biomarker technologies developed by researchers at Arizona State University's Biodesign Institute.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.